UK markets closed
  • FTSE 100

    -46.12 (-0.65%)
  • FTSE 250

    -101.67 (-0.44%)
  • AIM

    +3.84 (+0.31%)

    -0.0024 (-0.20%)

    -0.0050 (-0.35%)

    -289.94 (-0.97%)
  • CMC Crypto 200

    +5.13 (+0.54%)
  • S&P 500

    -23.89 (-0.54%)
  • DOW

    -149.03 (-0.42%)

    +0.19 (+0.26%)

    -18.70 (-1.02%)
  • NIKKEI 225

    -498.81 (-1.80%)

    -354.27 (-1.35%)
  • DAX

    -96.11 (-0.61%)
  • CAC 40

    -21.01 (-0.32%)

Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Visiongain Research Inc.

·6-min read

Visiongain has published a new report on Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Amyotrophic Lateral Sclerosis Treatment Market

The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Amyotrophic Lateral Sclerosis Treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Download Exclusive Sample of Report @

Market Drivers

Growing Occurrence of Amyotrophic Lateral Sclerosis
According to the statistics by the National Institute of Neurological Disorders and Stroke, following gradual paralysis, people with Amyotrophic Lateral Sclerosis often die from respiration failure within 3 to 5 years. NINSD also indicated that between the two types of Amyotrophic Lateral Sclerosis, the sporadic type is the typical form of the disease, estimating for 90% to 95% of all incidence took place in the U.S. while the familial type of the disease accounts for the rest.

Familial Amyotrophic Lateral Sclerosis (FALS) is genetic, where there is a 50% chance of receiving the hereditary mutation for each progeny and ultimately causing the disease. In 25-40% of the patient affected by the FALS, the fault is generally found in the C9ORF72 gene. Alteration in this gene also causes a disorder known as front temporal dementia (FTD), which may develop along with Amyotrophic Lateral Sclerosis as a co-morbidity known as ALS-FTD. Therefore, the growing incidence rate of ALS demands proper treatment to avoid any mortality, in turn, propelling the target industry growth.

Increasing Research and Developmental Activities for Treatment of ALS Disorder

Though there is no direct treatment for Amyotrophic Lateral Sclerosis, however treatments such as pills and stem cell therapies can aid in the managing of the indications, prevent unnecessary problems, and help to slow down the disease advancement.

Due to the great number of unmet requirements, companies operating in the market are focusing on the invention and technological developments in treatment options which force the growth of the ALS treatment market worldwide. The Amyotrophic Lateral Sclerosis clinical pipeline is robust and diverse, with late-stage programs which target at improving immune modulation, muscle function, and neuroprotection, along with mid or early-stage stem-cell therapies, gene therapy approaches, and immune-targeting agents and specialists, struggle that treatments joining multiple mechanisms of action could embrace major scientific promise in the management of ALS disease. Consequently, a substantial profitable opportunity exists for inventors that can overcome the technical and clinical issues hindering the path to governing endorsement for the treatment of ALS. For instance, In April 2018, Target ALS introduced new research that links the CReATe Consortium, 10 pharmaceutical companies, and the Muscular Dystrophy Association, to authorize the most promising Amyotrophic Lateral Sclerosis biomarker candidates, and instantaneously make all outcomes largely available to the globally ALS research community.

Market Opportunities

Availability of Funding for Research

Rising research & development activities and funding from government and numerous public-private organizations in stem cell studies are eventually contributing to the Amyotrophic Lateral Sclerosis Treatment market growth. The rising government initiatives in emerging economies, the existence of a huge number of drug product pipelines, and its therapeutic applications are the crucial factors fueling the demand for Amyotrophic Lateral Sclerosis Treatment, hence, aiding the target industry growth.

Get Detailed TOC @

How the Amyotrophic Lateral Sclerosis Treatment Market report helps you
In summary, our 500+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Amyotrophic Lateral Sclerosis Treatment Market, with forecasts for Treatment Type, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Amyotrophic Lateral Sclerosis Treatment market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted are the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Amyotrophic Lateral Sclerosis Treatment Market.

Competitive Landscape

Key players operating in the global Amyotrophic Lateral Sclerosis Treatment market are Sun Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, BrainStorm Therapeutics, Corestem, Biogen Inc., Biohaven Pharmaceutical, AB Science, F.Hoffmann-La Roche AG, Otsuka Pharmaceutical Co., Ltd., and Ionis Pharmaceuticals, Inc.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Amyotrophic Lateral Sclerosis Treatment market. For instance, In May 2019, Biogen Inc. publicized the short-term outcomes of phase 1 and 2 study of tofersen, which may be the possible treatment of ALS in elder people with a certain superoxide dismutase 1 (SOD1) alteration.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Amyotrophic Lateral Sclerosis Treatment Market and leading companies. Here you will find data, trends and predictions. Please order our report now.

Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.


Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Follow Us: LinkedIn | Twitter


SOURCE Visiongain Limited.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting